Following the referendum, the House of Commons’ Science and Technology Committee has
launched an inquiry to examine the implications and opportunities of leaving the EU for the UK science and research. Given the likely impact of UK-EU negotiations for our members and the wider public, it is important for the British Pharmacological Society to engage with this opportunity to share our insights and expertise.
The Society would like to respond to the inquiry by building on
the research we had released before the referendum, which already helped to outline the areas of interconnectivity between the UK’s broader pharmacological landscape and Europe.
A
new version of the document has been produced that includes an appendix (from page 12 onwards) summarising the recent developments in the post-referendum period relevant to pharmacology and clinical pharmacology. This appendix follows the original areas of priorities and concerns for pharmacology identified by the Society, which are:
- People
- Funding
- Regulation
- Impact on the pharmaceutical industry
This appendix will be used as part of the Society's response to inquries and other opportunities to inform policy development, by providing us with real life examples about pharmacology in the weeks since the referendum.